Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Other Non-Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Other Non-Current Assets for 3 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 35.91% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, down 35.91% year-over-year, with the annual reading at $4.4 million for FY2025, 35.91% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $4.4 million at Inhibrx Biosciences, down from $5.7 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $6.8 million in Q4 2024, with the low at $3.2 million in Q4 2023.
  • Average Other Non-Current Assets over 3 years is $5.9 million, with a median of $6.7 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets surged 115.9% in 2024, then plummeted 35.91% in 2025.
  • Over 3 years, Other Non-Current Assets stood at $3.2 million in 2023, then soared by 115.9% to $6.8 million in 2024, then crashed by 35.91% to $4.4 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $4.4 million, $5.7 million, and $6.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.